BIOX
Bioceres Crop Solutions Corp.Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nu
2-Year Price History
Quarterly Financials & Projections
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Est | 2028-Q3 | 33.0 | -1.0 | -- | -13.2 | -- | -5.9 | -0.7 | -6.6 | -- | -- | -- | -- | -- |
| Est | 2028-Q2 | 55.0 | 4.4 | -- | -6.6 | -- | 1.7 | -0.8 | -0.7 | -- | -- | -- | -- | -- |
| Est | 2028-Q1 | 48.0 | 2.9 | -- | -7.7 | -- | -2.4 | -0.7 | -2.3 | -- | -- | -- | -- | -- |
| Est | 2027-Q4 | 50.0 | 2.0 | -- | -10.0 | -- | -1.5 | -1.0 | 0.1 | -- | -- | -- | -- | -- |
| Est | 2027-Q3 | 35.0 | -0.7 | -- | -12.3 | -- | -5.3 | -0.7 | 1.6 | -- | -- | -- | -- | -- |
| Est | 2027-Q2 | 58.0 | 4.1 | -- | -8.7 | -- | 1.2 | -0.9 | 6.8 | -- | -- | -- | -- | -- |
| Est | 2027-Q1 | 52.0 | 2.6 | -- | -9.4 | -- | -4.2 | -0.8 | 5.7 | -- | -- | -- | -- | -- |
| Est | 2026-Q4 | 55.0 | 1.7 | -- | -13.8 | -- | -2.8 | -0.8 | 9.8 | -- | -- | -- | -- | -- |
| Act | 2026-Q2 | 73.7 | 6.8 | 7.8 | -183.0 | 14.3 | 3.9 | -0.0 | 12.6 | 239.5 | 63.5 | 8.5% | 1.0x | 25.9x |
| Act | 2026-Q1 | 77.4 | 9.3 | 6.8 | -7.3 | 10.5 | -0.6 | -0.7 | 16.6 | 267.7 | 63.4 | 4.5% | 1.0x | 31.5x |
| Act | 2025-Q4 | 74.4 | -10.7 | -14.9 | -44.3 | 26.8 | -4.4 | -2.2 | 34.7 | 276.6 | 63.2 | -13.3% | -0.4x | 34.4x |
| Act | 2025-Q3 | 59.6 | 6.6 | 0.9 | -1.3 | 23.3 | 11.2 | -3.2 | 39.4 | 273.3 | 62.8 | 0.8% | 1.1x | 18.8x |
| Act | 2025-Q2 | 106.8 | 11.9 | 7.9 | 0.1 | -5.4 | -27.3 | -2.7 | 31.2 | 285.6 | 63.2 | 6.2% | 1.6x | 15.4x |
| Act | 2025-Q1 | 92.6 | 7.3 | 2.4 | -5.5 | 5.2 | -7.3 | -3.1 | 38.2 | 266.6 | 62.9 | 1.9% | 1.2x | 16.5x |
| Act | 2024-Q4 | 124.3 | 9.1 | 9.5 | -1.5 | 23.3 | 4.0 | -6.1 | 56.2 | 271.0 | 60.6 | 7.5% | 1.3x | 17.2x |
| Act | 2024-Q3 | 84.0 | 20.1 | 13.2 | 9.3 | -17.4 | -29.1 | -1.7 | 32.8 | 255.1 | 66.8 | 10.7% | 4.6x | 19.5x |
| Act | 2024-Q2 | 140.3 | 19.7 | 16.8 | 0.1 | 21.1 | -10.7 | -4.8 | 41.4 | 236.6 | 63.9 | 9.3% | 2.7x | 12.7x |
| Act | 2024-Q1 | 116.2 | 9.6 | 5.3 | -4.6 | 14.7 | -0.2 | -6.0 | 43.0 | 249.3 | 62.9 | 4.1% | 1.4x | 19.8x |
| Act | 2023-Q4 | 105.1 | 5.9 | 5.1 | -1.7 | -8.5 | -25.1 | -6.6 | 60.1 | 257.4 | 62.8 | 4.1% | 1.0x | 14.6x |
| Act | 2023-Q3 | 93.0 | 34.5 | 29.9 | 28.2 | 2.3 | -8.0 | -6.1 | 70.7 | 263.9 | 63.1 | 23.6% | -- | 13.5x |
| Act | 2023-Q2 | 94.6 | 3.5 | 2.2 | -8.2 | 41.2 | 24.7 | -5.0 | 87.4 | 280.3 | 61.7 | 1.3% | 0.3x | 25.9x |
| Act | 2023-Q1 | 126.8 | 19.2 | 17.0 | 0.5 | -32.4 | -46.2 | -4.9 | 51.3 | 252.4 | 61.7 | 10.2% | 2.8x | 17.7x |
| Act | 2022-Q4 | 101.6 | 11.3 | 10.0 | -5.0 | -5.4 | -14.0 | -2.0 | 38.6 | 169.8 | 45.9 | 10.5% | 2.3x | 16.9x |
| Act | 2022-Q3 | 68.2 | 5.0 | 2.2 | -6.5 | 7.8 | -2.1 | -2.5 | 41.0 | 206.4 | 41.1 | 2.3% | 1.1x | -- |
| Act | 2022-Q2 | 92.3 | 19.4 | 17.7 | 3.4 | -6.1 | -18.7 | -2.0 | 39.7 | 189.1 | 42.4 | 24.3% | 2.4x | -- |
| Act | 2022-Q1 | 66.4 | 9.3 | 10.0 | 0.9 | -13.7 | -22.3 | -2.6 | 41.7 | 180.7 | 42.4 | 14.6% | 2.8x | -- |
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| 2022 | 12.03 | — | 13.7% | 45 | 21.1× | n/m | n/m | 2.5× |
| 2023 | 13.73 | +27.7% | 15.0% | 63 | 14.1× | n/m | 36.7× | 1.6× |
| 2024 | 6.08 | +10.8% | 12.6% | 59 | 12.1× | n/m | 152.2× | 1.1× |
| 2025 | 1.31 | -28.3% | 4.6% | 15 | 21.6× | n/m | n/m | 0.3× |
| TTM | 0.45 | -30.1% | 4.2% | 12 | 0.0× | 0.0× | 0.0× | 0.0× |
| 2027E | 0.45 | -31.6% | 0.0% | 0 | 0.0× | 0.0× | 0.0× | 0.0× |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
AI Analysis
LLM Evaluations
Bioceres is a deeply distressed agricultural biotech company facing existential threats on multiple fronts. The company has a going concern warning, $229M in accelerated debt against ~$12M in cash, ongoing litigation with creditors who have already foreclosed on its most valuable international assets (Pro Farm), and reported bankruptcy proceedings against the parent entity in Argentina. Revenue is declining 20-30% YoY, EBITDA margins are near zero, and interest expense consumes over 10% of revenue. The HB4 wheat technology—once the core bull thesis—faces credibility challenges with field performance below claims. Even in a best-case scenario where debt is successfully restructured, the remaining Argentine-centric business generates insufficient cash flow to service obligations, and equity holders are deeply subordinated. The 2.4% short interest is surprisingly low given the fundamental severity, suggesting either limited borrow availability or the market already pricing in near-zero equity value at $0.45/share ($28M market cap). This is a potential zero.
Latest Earnings Call
Transcript Summary
Bioceres Crop Solutions' Q3 2026 results were overshadowed by a $179 million non-cash loss following the foreclosure of Pro Farm Group assets by noteholders. Total revenue declined 23% year-over-year to $39.4 million, driven by a 71% drop in the Seeds segment as the company transitions to an asset-light model and an 18% decline in Crop Protection. Adjusted EBITDA fell to negative $0.6 million, compared to positive $9.1 million in the prior year, hampered by the lack of IP income and an inoculant obsolescence adjustment. The company is currently embroiled in litigation in New York over the purported acceleration of secured notes, leading to the reclassification of $229 million in debt as short-term. Management, led by CEO Federico Trucco and new CFO Ezequiel Simmermacher, is prioritizing liquidity preservation, cost-cutting, and debt reprofiling for its Rizobacter subsidiary. Despite growth in Crop Nutrition, the company faces significant hurdles regarding its legal standing and debt obligations. The call concluded with a brief Q&A where management discussed receivable collection strategies but deferred specific cash flow queries, underscoring the ongoing focus on stabilizing operations amidst high uncertainty and significant legal risk.
Valuation & Metrics
Market Stats
TTM Financial Snapshot
DCF Fair Value Estimate
Forward Outlook & Risk
Short Interest
Options
| Strike | Call Bid/Ask | Call OI | Put Bid/Ask | Put OI |
|---|---|---|---|---|
| $2.50 | --/$0.05 | 30 | $1.15/$2.50 | 0 |
| $5.00 | --/$1.35 | 90 | $3.70/$5.00 | 0 |
| $7.50 | --/$1.40 | 95 | $6.20/$7.50 | 0 |
Forward Projections & Estimates
Employees
Institutional Ownership
Headline & net flow
In Q1 2026 so far (quarter still filing), institutions are net sellers — bought 1.7% of float, sold 10.7%. 1 filer moved >1% of shares (0 buying, 1 selling).
Ownership composition
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Solel Partners LP | $2.0M | $13.71 | +$0 | +$0 | -1.7% | $468M |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $478K | $5.98 | +$44K | +$111K | +1.7% | $73.71B |
| Long Focus Capital Management, LLC | $369K | $7.93 | +$0 | +$0 | -1.5% | $2.22B |
| MARSHALL WACE, LLP | $309K | $1.82 | +$48K | +$309K | +0.6% | $92.71B |
| ARDSLEY ADVISORY PARTNERS LP | $211K | $10.71 | +$0 | −$211K | -0.6% | $656M |
| UBS Group AG | $159K | $3.15 | +$117K | +$118K | -0.3% | $562.11B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $96K | $2.91 | −$7K | +$96K | -0.6% | $77.14B |
| STATE OF WISCONSIN INVESTMENT BOARD | $84K | $1.31 | +$0 | +$84K | -0.2% | $43.36B |
| PNC FINANCIAL SERVICES GROUP, INC. | $59K | $13.36 | +$0 | −$8K | +0.3% | $173.16B |
| Invesco Ltd. | $56K | $0.68 | +$41K | +$56K | -0.2% | $652.04B |
| GOLDMAN SACHS GROUP INC | $52K | $3.38 | +$4K | +$52K | -0.2% | $760.93B |
| TWO SIGMA INVESTMENTS, LP | $42K | $0.57 | +$36K | +$42K | -0.9% | $117.03B |
| STIFEL FINANCIAL CORP | $37K | $6.74 | −$3K | +$5K | -0.3% | $108.17B |
| PING CAPITAL MANAGEMENT, INC. | $24K | $9.37 | +$0 | −$0 | +7.6% | $259M |
| SIMPLEX TRADING, LLC | $20K | $3.60 | +$7K | +$20K | +2.5% | $3.23B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $17K | $12.62 | +$0 | +$0 | +2.3% | $1.61T |
| JANE STREET GROUP, LLCMM | $15K | $2.71 | −$20K | +$15K | -0.1% | $92.10B |
| One Degree Advisors Inc | $10K | $13.73 | +$0 | +$0 | +0.5% | $381M |
| R Squared Ltd | $10K | $1.16 | +$4K | +$10K | +0.8% | $182M |
| MORGAN STANLEY | $8K | $10.41 | +$6K | −$35K | -0.3% | $1.65T |
Trading behavior
▸ Compare to holder-profile behavior (across all their stocks)
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 82.8%
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Analyst Coverage
| Quarter | Revenue | EBITDA | Net Inc | EPS | EPS Range | # Analysts |
|---|---|---|---|---|---|---|
| 2024 Q1 | 99M | 14M | 11M | $0.17 | $0.14 – $0.18 | 4 |
| 2024 Q2 | 134M | 19M | 15M | $0.23 | $0.22 – $0.23 | 3 |
| 2024 Q3 | 110M | 15M | -1M | $-0.02 | $-0.10 – $0.08 | 3 |
| 2024 Q4 | 124M | 17M | 6M | $0.10 | $0.09 – $0.10 | 2 |
| 2025 Q1 | 63M | 9M | -8M | $-0.12 | $-0.29 – $0.04 | 2 |
| 2025 Q2 | 110M | 15M | 4M | $0.07 | $0.03 – $0.10 | 2 |
| 2025 Q3 | 95M | 13M | -4M | $-0.06 | $-0.08 – $-0.05 | 2 |
| 2025 Q4 | 96M | 13M | 4M | $0.07 | $0.07 – $0.07 | 1 |
| 2026 Q1 | 55M | 8M | -3M | $-0.05 | $-0.05 – $-0.05 | 1 |
| 2026 Q2 | 79M | 11M | -4M | $-0.06 | $-0.06 – $-0.06 | 1 |
Corporate
Order Flow (FINRA, ~3w lag)
Revenue Breakdown
Revenue Segments
| Product | $10.4M | NEW |
| License | $0.2M | NEW |
Filing Risk Analysis
Filing Risk Scores
Bioceres Crop Solutions: Terminal Insolvency and Fire-Sale Foreclosure of Core Assets
Counter-Thesis
Counter-Thesis & Recent News
On May 11, 2026, Bioceres reported a massive Q3 2026 revenue miss ($39.4M vs. $54.5M expected) and a net loss of $10M. This follows a catastrophic Q2 fiscal 2026 report where the company disclosed a $179 million impairment charge related to the foreclosure auction of its Pro Farm Group (PFG) assets in January 2026. Additionally, a major creditor, Jasper Lake Ventures One LLC, filed a lawsuit in late 2025 demanding immediate repayment of $48.5 million in accelerated debt, representing nearly 45% of the company's market cap at the time (Source: Zacks, Stock Titan, Reddit/SEC Filings).
The core bull thesis for BIOX—its 'drought-resistant' HB4 wheat—is under intense scrutiny. Recent field analysis by researchers in Argentina and Brazil suggests HB4 wheat yields are up to 17% lower than conventional varieties, calling into question the 20% yield-increase claims. Furthermore, the company officially disclosed 'substantial doubt' about its ability to continue as a going concern in March 2026 following the PFG foreclosure and ongoing liquidity crises. The transition to an 'asset-light' seed model has resulted in a 23-40% year-over-year revenue decline (Source: GMWatch, Simply Wall St).
In March 2026, a court in Rosario, Argentina, reportedly initiated bankruptcy proceedings against the parent company, Bioceres SA, following a rift between major shareholders and defaults. Management has been forced into a 'voluntary bond maturity extension' in Argentina to manage liabilities. The company's 'Financial Strength' is currently rated 3/10 by GuruFocus, and it has missed both EPS and revenue estimates for four consecutive quarters as of May 2026 (Source: GuruFocus, La Nación).
BIOX is facing 'softer demand and competitive pressures' in its Crop Protection segment, particularly in its primary market of Argentina. The company is losing market share to established giants like Corteva and Nutrien as its biologicals and HB4 seed rollout stalls due to financial instability. The foreclosure of its North American biologicals arm (Pro Farm) severely weakens its ability to compete in the U.S. market against specialized biotech startups and incumbents (Source: Stock Titan).
Farmer and civil society sentiment is turning negative; organizations in Argentina and Paraguay have called for a definitive suspension of HB4 wheat sales, citing 'commercial failure' and technological underperformance. Reports of HB4 wheat failing to show drought tolerance in actual field conditions have damaged the brand's credibility with local agricultural cooperatives who initially held high expectations (Source: Biodiversidad en América Latina).
Full Earnings Call Transcript
Full Earnings Call Transcript — Q3 • 2026-05-12
Operator: Hello, everyone. Thank you for joining us, and welcome to Bioceres Crop Solutions Fiscal Third Quarter 2026 Financial and Operational Results Call. [Operator Instructions] I will now hand the conference over to Paula Savanti, Head of Investor Relations. Paula, please go ahead. Paula Savanti: Thank you, and good morning, everyone. Welcome to Bioceres Crop Solutions Third Fiscal Quarter 2026 Earnings Conference Call. Our prepared remarks today will be led by our Chief Executive Officer, Federico Trucco; our General Counsel, Jose Roque; and our Chief Financial Officer, Ezequiel Simmermacher. All of them will be available for the Q&A session following the presentation. During this call, we will be making forward-looking statements. These statements are based on current expectations and assumptions that are subject to various risks and uncertainties. I refer you to the forward-looking statements section of the earnings release and presentation as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. In today's presentation, we will be making references to certain non-GAAP financial measures. Reconciliations of the non-GAAP measures can be found in our earnings press release. This conference call is being webcast, and the link is available at our Investor Relations website. It is now my pleasure to turn the call over to Federico. Federico Trucco: Thanks, Paula, and good morning to everyone. Thanks for joining us today. Please turn to Slide 3 for today's key business and financial highlights. This quarter reflects a period of transition and operational refocusing for the company, while it is historically our weakest quarter from a baseline business perspective. Total revenues and gross profits showed a decline compared to the same quarter last year, which was partially offset by an improvement in operational expenses. Net loss was $10 million, primarily reflecting lower gross profit as well as increased financial expenses, all of which will be described in greater detail later in the presentation. Also, in the last 3 years, we have booked profits from IP rights and other commercial arrangements in this quarter, which helped us offset baseline operating losses. Although we continue to explore strategic arrangements with our partners on a regular basis and see these as a recurrent source of profitability, this year, the timing of profit-generating arrangements did not coincide with the initial months of the calendar year. As I have stated in my message to shareholders of March 16, we recognize the significance of the events surrounding Pro Farm and the uncertainty generated by the ongoing litigation process. Jose Roque, our General Counsel, will now provide an update of the ongoing litigation. Please turn to Slide 4. Jose Roque: Thank you, Federico, and good morning to everyone on the call. As previously disclosed, in November 2025, 4 holders of secured notes issued under our note purchase agreements dated August 2022, filed a lawsuit in New York against the company and certain guarantor affiliates. The plaintiffs alleged that defaults occurred under those agreements and are seeking payment of amounts they say became immediately due. The company strongly disputes the allegations. As explained in court filings, each of the alleged defaults turns on contested facts. The company has, at all times, acted in good faith and under active Board supervision to manage liquidity and preserve enterprise value. We have also asserted counterclaims against the plaintiffs and third-party individuals. On January 20, 2026, as part of the litigation process, the noteholders conducted a foreclosure auction involving the Pro Farm Group, Inc. collateral. A noteholder affiliated entity was the only qualified bidder and acquired the assets through a $15 million credit bid. We believe and continue to argue in litigation that the foreclosure was conducted in a commercially unreasonable manner, and we have asserted counterclaims challenging the process. The case remains in its early stages, and the company intends to continue both our active defense against noteholders' allegations and the pursuit of our affirmative claims. While we remain confident in our legal position, I would remind listeners that my statements regarding the litigation are subject to the usual disclaimers regarding forward-looking statements and that actual results may differ materially. The company intends to continue updating shareholders regarding material developments in the litigation through appropriate disclosures, including, where applicable, reports on Form 6-K. Federico Trucco: Thank you, Jose. Please now turn to Slide #5 for an introduction to Ezequiel Simmermacher, who joined us as CFO at the beginning of the year. Ezequiel comes to us after a nearly 20-year career in agriculture with positions of increasing seniority at Monsanto first and then at CHS, where he was Regional Finance Director and then Director of Operational Excellence for South America until joining us. We're delighted to have Ezequiel in the team and very grateful for his commitment to our organization, particularly in light of joining at a time of significant uncertainty. Ezequiel, welcome. Now turning the call over to you to discuss the accounting impact of the Pro Farm foreclosure as well as the quarter's financial performance for our continuing operations. Ezequiel Simmermacher: Thank you, Federico, for the introduction, and good morning, everyone. It is great to be here in my first earnings call with Bioceres. Let's begin with Slide 6, which, as Federico mentioned, detail the impact of the January 2026 foreclosure auction involving the Pro Farm Group on our financials. As a result of the foreclosure process, the Pro Farm business was classified as discontinued operations and its assets and liabilities were reclassified accordingly in our financial statements. Based on the expected proceeds from the foreclosure auction, the company recognized a noncash impairment and loss associated with the transaction during the second quarter of fiscal year 2026. In total, approximately $194 million of the net assets associated with the Pro Farm Group business was recognized or reclassified. After considering the $15 million credit bid submitted by noteholders, this results in accumulated noncash loss of approximately $179 million. The largest impact were reductions in intangible assets and goodwill, together with reductions in property, plant and equipment and working capital balance. These were partially offset by the derecognition of liabilities associated with the Pro Farm Group business. These impacts were recognized in the second quarter and are reflected in the current balance sheet presentations. Now let's walk through the financial results for the quarter. And first, let me remind you that all financial results discussed below reflect the company's continuing operations for all periods presented and previous year's amounts have been recast to exclude the Pro Farm Group business unless otherwise noted. Let's turn to Slide 7 to begin looking at revenues. Total revenues for the quarter were $39.4 million, representing a 23% decline versus the same period last year. Before discussing the segments, I think it's important to remember that the fiscal third quarter is seasonally the lowest quarter for our continuous operation, particularly following the Pro Farm foreclosure auction and the resulting reduction in North America operations. This quarter typically coincides with lower planting and harvesting activities in the Southern Hemisphere, meaning that fluctuation in demand, pricing and product mix tend to have a more visible impact on quarterly performance. Looking at segment performance, we saw a mixed dynamic across the portfolio. In Crop Protection, revenue were $24.6 million, down 18% year-over-year. The decline was mainly driven by softened demand and competitive pressure in certain categories, particularly in adjuvants and third-party products in Argentina. We also continue to see inventory adjustments across the nutrition channel, which affected purchasing activity. In third-party products, pricing pressure in both patent categories also weighted on revenues. In Seeds and Integrated Products revenues declined 71% year-over-year. This continues the trend we've seen over the last several quarters as downstream seeds and grain sales are phased out as part of the strategic shift towards a more asset-light and lower working capital-intense model in seeds. As we've discussed before, this transition reduced reported revenues in the near term while also lowering exposure to lower margin and more working capital-intense activity. Crop Nutrition was the one segment that posted growth during the quarter, with revenues increased 15% year-over-year to $11.6 million. Growth was mainly driven by micro fertilizer supported by a low comparable base and stronger demand dynamics during the quarter amid global supply and pricing uncertainties associated with geopolitical tensions. Overall, revenue performance during the quarter reflects a combination of softer market conditions in certain categories together with ongoing portfolio transition effects. Moving now to gross profit on Slide 8. Gross profit for the quarter was $12.7 million compared to $18.1 million in the same period last year, representing a 30% year-over-year decline. The decline was relatively broad-based across the 3 segments. In Crop Protection, gross profit performance largely mirrored the decline in revenues. Margins across the different product categories were generally stable, although overall segment margin came down from 37% to 35%, mainly due to the lower contribution from adjuvants within the mix this quarter. In Seeds and Integrated Products, gross profit declined in absolute terms, but significantly less than revenues. As a result, gross margin improved from 19% to 30%, reflecting a more favorable mix with a higher relative contribution from seed treatment packs versus downstream grain sales. Finally, Crop Nutrition gross profit declined 38% despite higher revenues. The main driver here was obsolescence adjustment related to inoculants following an update inventory assessment during this quarter. Excluding this adjustment, underlying profitability in the inoculants business remained broadly stable year-over-year. Overall, gross margin declined from 35% to 32%, reflecting lower revenues, product mix effects and inoculants adjustment disclosed above. Excluding that nonrecurring adjustment, underlying gross margin performance remains broadly in line with the prior year period. Now let's please turn to Slide 9 for a review of the adjusted EBITDA. Adjusted EBITDA for the quarter was negative $0.6 million compared to positive $9.1 million in the prior year quarter. When looking at this year-over-year comparison, it is important to separate a couple of nonrecurring items affecting comparability across periods. First, the prior year quarter included approximately $7.7 million of nonrecurring other income associated with changes in contractual obligations and intellectual property arrangements as part of the recognition -- reorganization in Seeds. The absence of that income had a significant impact on comparability versus last year. Second, during the current quarter, Crop Nutrition results were impacted by a nonrecurring inoculant obsolescence adjustment associated with an updated inventory assessment. Looking beyond these items, underlying operations performance reflects lower gross profit across part of the business, particularly in Crop Protection, although the deterioration was partially offset by continuous progress on cost control, organizational streamlining initiatives. These actions resulted in a meaningful reduction in operation expense during the quarter, while joint ventures results also improved year-over-year and provided an additional positive contribution to EBITDA. Finally, let's turn to Slide #10 to review our balance sheet, cash position and a brief update on the debt situation. As of March 31, 2026, total financial debt stood at approximately $229 million, broadly stable compared to the previous quarter. Cash, cash equivalents and short-term investments totaled approximately $14 million, resulting in a net financial debt of approximately $214 million, also stable on a sequential basis. One important point to highlight is that following the acceleration notice received in connection with the noteholder situation discussed earlier in the call, substantially all of the related debt is currently classified as short term in our balance sheet presentation. As Federico and Jose previously noted, the company continues to dispute both the purported acceleration of the notes and the commercial reasonable of the Pro Farm foreclosure action. These matters remain subject to ongoing legal proceeding, and the company intends to continue vigorously defending its position and pursuing its claim and counterclaims in the litigation. At the same time, we continue to evaluate constructive alternatives and maintaining dialogue with relevant stakeholders where appropriate. As Federico mentioned earlier, we are also advancing a reprofiling process for Rizobacter debt obligation in Argentina, including voluntary maturity extensions, discussions with bondholders and continued coordination with key banking partners. More broadly, management remains highly focused on liquidity preservation, working capital discipline and tighter capital allocation across the organization as we continue to stabilize the platform and improve financial flexibility over time. With that, I will turn the call back over to Federico. Thank you. Federico Trucco: Thanks, Ezequiel. And please turn to Slide 11, our final slide for today. While market conditions in several areas of our business remain challenging and the effects of the transition in Seeds continue to weigh on reported results, we are increasingly focused on strengthening the fundamentals of the organization and prioritizing disciplined execution across the business. During the quarter, we continued advancing initiatives aimed at simplifying the organization, improving operational efficiency, strengthening working capital management and improving cash generation while advancing liability management initiatives across key operating subsidiaries. In parallel, we are reinforcing governance and internal processes and concluding a strategic review of our continuing -- and conducting a strategic review of our continuing operations including initiatives focused on organizational streamlining and capital allocation optimization to ensure that capital management attention and resources remain aligned with the areas where we believe we can create the greatest long-term value. We recognize the uncertainty generated by the ongoing litigation. While we continue to pursue the appropriate legal course and evaluate constructive alternatives where possible, our priority remains clear, stabilizing the business, preserving the value of our core operations and positioning the company for a more resilient and sustainable future. With that, I think we can now turn the call over to Q&A. Operator: [Operator Instructions] Your first question comes from the line of Kemp Dolliver with Brookline Capital Markets. Brian Kemp Dolliver: I did miss the first few minutes of the presentation, but I think you can go to add some information on this. What are you doing with regard to collections? It looks like you've made some progress on reducing receivables, but it's hard to tell given the restatements where you stand currently on that initiative. Federico Trucco: I will pass that question over to Ezequiel. And first, I'll say that we're emphasizing, obviously, reducing receivables and advancing collections to prioritize liquidity and keep working capital discipline. But Ezequiel might be able to provide more color into this. Ezequiel Simmermacher: 2 angles. First is we have been working on, let's say, giving alternatives to our customers to advance the receivables with some type of incentive. And on the other side, we have been working on new sales being done in lower sell period by giving some attractive to shorter terms that are more common to the industry. Brian Kemp Dolliver: Okay. And what was operating cash flow for the quarter and then year-to-date? Ezequiel Simmermacher: No, we can provide that after. Federico Trucco: We don't have the number, the exact number here, but we can provide that information on the analyst session with you. Operator: As there are no further questions at this time, I will turn the call back to Federico Trucco for closing remarks. Federico Trucco: Thank you, and thanks again, everyone, for joining. We remain available for any additional information that might be required. And hope everyone has a great rest of the week. Operator: And this concludes today's call. Thank you all for attending. You may now disconnect.